Status:
COMPLETED
Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis
Lead Sponsor:
Pfizer
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of study is to explore the effect of CP-690,550 (tasocitinib) on cholesterol metabolism in patients with active rheumatoid arthritis (RA).
Eligibility Criteria
Inclusion
- Males or females, 18 years of age or older with active rheumatoid arthritis; Or male and female healthy volunteers 18 years of age and older
Exclusion
- Pregnant or lactating women
- Clinically significant systemic disease (other than RA for RA arm)
- Use of lipid-regulating agents
Key Trial Info
Start Date :
May 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT01262118
Start Date
May 1 2011
End Date
February 1 2012
Last Update
January 23 2013
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Anniston, Alabama, United States, 36201
2
Pfizer Investigational Site
Anniston, Alabama, United States, 36207
3
Pfizer Investigational Site
Little Rock, Arkansas, United States, 72201
4
Pfizer Investigational Site
Los Angeles, California, United States, 90095